MediWound Ltd. (MDWD) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low11.6·High11.6
P/FCF
N/A
—
5yr avg: N/A
30Y Low11.2·High11.2
P/B Ratio
↓
4.50
-8% vs avg
5yr avg: 4.89
30Y Low2.9·High13.8
ROE
↑
-63.9%
↓+82% vs avg
5yr avg: -363.7%
30Y Low-255%·High70%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.3·High0.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MDWD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
MediWound Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $222M | $210M | $177M | $92M | $67M | $64M | $101M | $84M | $110M | $104M | $100M |
| Enterprise Value | $226M | $214M | $175M | $86M | $34M | $55M | $85M | $79M | $103M | $68M | $71M |
| P/E Ratio → | -8.22 | — | — | — | — | — | — | 17.22 | — | — | — |
| P/S Ratio | 13.07 | 12.38 | 8.77 | 4.91 | 2.54 | 2.71 | 4.63 | 2.65 | 32.36 | 41.61 | 64.24 |
| P/B Ratio | 4.50 | 4.81 | 5.69 | 2.90 | 6.16 | — | 13.84 | 5.55 | 12.27 | 10.80 | 12.88 |
| P/FCF | — | — | — | — | — | — | — | 11.24 | — | — | — |
| P/OCF | — | — | — | — | — | — | — | 10.17 | — | — | — |
P/E links to full P/E history page with 30-year chart
MDWD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 12.62 | 8.66 | 4.61 | 1.29 | 2.30 | 3.91 | 2.49 | 30.39 | 27.16 | 45.72 |
| EV / EBITDA | — | — | — | — | — | — | — | 11.60 | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | 34.77 | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | 10.54 | — | — | — |
MDWD Profitability
Margins and return-on-capital ratios measuring operating efficiency
MediWound Ltd. earns an operating margin of -149.1%. Operating margins have compressed from -83.0% to -149.1% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -63.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 12.6% | 12.6% | 8.8% | 15.8% | 46.5% | 34.2% | 32.2% | 60.7% | 35.6% | 32.4% | -45.7% |
| Operating Margin | -149.1% | -149.1% | -95.9% | -83.0% | -28.9% | -47.2% | -40.6% | 17.8% | -316.0% | -548.4% | -1293.6% |
| Net Profit Margin | -140.8% | -140.8% | -149.5% | -35.9% | -74.0% | -57.0% | -42.3% | 15.6% | -31.1% | -887.4% | -1212.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -63.9% | -63.9% | -96.3% | -31.6% | -619.0% | -1007.5% | -82.0% | 41.1% | -11.4% | -254.7% | -120.9% |
| ROA | -29.9% | -29.9% | -43.2% | -11.5% | -56.2% | -53.3% | -25.7% | 13.1% | -2.7% | -55.4% | -42.8% |
| ROIC | -49.5% | -49.5% | -52.9% | -589.5% | — | — | -844.6% | 69.7% | — | — | — |
| ROCE | -47.0% | -47.0% | -37.8% | -33.1% | -32.6% | -70.5% | -33.3% | 18.7% | -31.1% | -39.6% | -51.9% |
MDWD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $4M ($9M total debt minus $5M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.20 | 0.22 | 0.20 | 0.08 | — | 0.24 | 0.13 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | 0.29 | — | — | — |
| Net Debt / Equity | — | 0.09 | -0.07 | -0.17 | -3.03 | — | -2.15 | -0.35 | -0.75 | -3.75 | -3.72 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | -0.77 | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -0.70 | — | — | — |
| Interest Coverage | -38.13 | -38.13 | -34.55 | -46.27 | -47.29 | -67.19 | -44.20 | 27.37 | — | — | — |
MDWD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
MediWound Ltd.'s current ratio of 2.33x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.59x to 2.33x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.33 | 2.33 | 1.97 | 4.59 | 3.80 | 1.39 | 3.17 | 3.43 | 6.68 | 7.64 | 6.25 |
| Quick Ratio | 2.17 | 2.17 | 1.86 | 4.33 | 3.64 | 1.28 | 3.00 | 3.28 | 6.34 | 7.30 | 6.09 |
| Cash Ratio | 2.07 | 2.07 | 1.63 | 3.84 | 2.81 | 1.03 | 2.59 | 2.82 | 4.83 | 6.64 | 5.58 |
| Asset Turnover | — | 0.20 | 0.28 | 0.28 | 0.53 | 1.20 | 0.70 | 0.78 | 0.10 | 0.06 | 0.04 |
| Inventory Turnover | 3.62 | 3.62 | 6.85 | 5.53 | 7.22 | 13.02 | 10.69 | 7.74 | 1.30 | 0.90 | 2.69 |
| Days Sales Outstanding | — | 51.05 | 105.63 | 86.32 | 133.56 | 34.82 | 47.63 | 49.77 | 780.01 | 502.46 | 641.68 |
MDWD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
MediWound Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 5.8% | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | 8.9% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $11M | $10M | $9M | $5M | $4M | $4M | $4M | $4M | $3M | $3M |
Peer Comparison
Compare MDWD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MDWDYou | $222M | -8.2 | — | — | 12.6% | -149.1% | -63.9% | -49.5% | — |
 SLXN | $2M | -0.1 | — | — | — | — | -457.6% | — | — |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 BLFS | $1B | -92.5 | — | 106.2 | 64.6% | -12.6% | -3.4% | -2.8% | — |
 KROS | $433M | 5.1 | 2.3 | 4.1 | 99.4% | 28.9% | 19.9% | 167.9% | 0.2 |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 XTLB | $293767 | -0.3 | — | — | 0.7% | -481.6% | -26.8% | -54.1% | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 SYK | $113B | 35.0 | 20.3 | 26.3 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
 BSX | $84B | 29.2 | 25.3 | 23.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See MDWD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MDWD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MDWD vs SLXN
Side-by-side business, growth, and profitability comparison vs Silexion Therapeutics Ltd..
Start ComparisonMDWD — Frequently Asked Questions
Quick answers to the most common questions about buying MDWD stock.
What is MediWound Ltd.'s P/E ratio?
MediWound Ltd.'s current P/E ratio is -8.2x. The historical average is 17.2x.
What is MediWound Ltd.'s ROE?
MediWound Ltd.'s return on equity (ROE) is -63.9%. The historical average is -70.9%.
Is MDWD stock overvalued?
Based on historical data, MediWound Ltd. is trading at a P/E of -8.2x. Compare with industry peers and growth rates for a complete picture.
What are MediWound Ltd.'s profit margins?
MediWound Ltd. has 12.6% gross margin and -149.1% operating margin.